BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study

A Barnadas; M Muñoz; M Margelí; J I Chacón; J Cassinello; S Antolin; E Adrover; M Ramos; E Carrasco; M A Jimeno; B Ojeda; X González; S González; M Constenla; J Florián; A Miguel; A Llombart; A Lluch; M Ruiz-Borrego; R Colomer; S Del Barco

doi:10.1186/s41687-019-0161-y

BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study

A Barnadas, M Muñoz, M Margelí, J I Chacón, J Cassinello, S Antolin, E Adrover, M Ramos, E Carrasco, M A Jimeno, B Ojeda, X González, S González, M Constenla, J Florián, A Miguel, A Llombart, A Lluch, M Ruiz-Borrego, R ColomerS Del Barco

Department of Medicine

Research output: Contribution to journal › Article › Research › peer-review

2 Citations (Scopus)

Abstract

BACKGROUND: Bone metastasis (BM) is the most common site of disease in metastatic breast cancer (MBC) patients. BM impacts health-related quality of life (HRQoL). We tested prospectively the psychometric properties of the Bone Metastasis Quality of Life (BOMET-QoL-10) measure on MBC patients with BM.

METHODS: Patients completed the BOMET-QoL-10 questionnaire, the Visual Analogue Scale (VAS) for pain, and a self-perceived health status item at baseline and at follow-up visits. We performed psychometric tests and calculated the effect size of specific BM treatment on patients´ HRQoL.

RESULTS: Almost 70% of the 172 patients reported symptoms, 23.3% experienced irruptive pain, and over half were receiving chemotherapy. BOMET-QoL-10 proved to be a quick assessment tool performing well in readability and completion time (about 10 min) with 0-1.2% of missing/invalid data. Although BOMET-QoL-10 scores remained fairly stable during study visits, differences were observed for patient subgroups (e.g., with or without skeletal-related events or adverse effects). Scores were significantly correlated with physician-reported patient status, patient-reported pain, symptoms, and perceived health status. BOMET-QoL-10 scores also varied prospectively according to changes in pain intensity.

CONCLUSIONS: BOMET-QoL-10 performed well as a brief, easy-to-administer, useful, and sensitive HRQoL measure for potential use for clinical practice with MBC patients.

TRIAL REGISTRATION: NCT03847220. Retrospectively registered on clinicaltrials.gov (February the 20th 2019).

Original language	English
Pages (from-to)	72
Journal	Journal of Patient-Reported Outcomes
Volume	3
Issue number	1
DOIs	https://doi.org/10.1186/s41687-019-0161-y
Publication status	Published - 21 Dec 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/s41687-019-0161-y

Cite this

Barnadas, A., Muñoz, M., Margelí, M., Chacón, J. I., Cassinello, J., Antolin, S., Adrover, E., Ramos, M., Carrasco, E., Jimeno, M. A., Ojeda, B., González, X., González, S., Constenla, M., Florián, J., Miguel, A., Llombart, A., Lluch, A., Ruiz-Borrego, M., ... Del Barco, S. (2019). BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study. Journal of Patient-Reported Outcomes, 3(1), 72. https://doi.org/10.1186/s41687-019-0161-y

@article{c1eb29f8be5c46a9b227649507736c68,

title = "BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study",

abstract = "BACKGROUND: Bone metastasis (BM) is the most common site of disease in metastatic breast cancer (MBC) patients. BM impacts health-related quality of life (HRQoL). We tested prospectively the psychometric properties of the Bone Metastasis Quality of Life (BOMET-QoL-10) measure on MBC patients with BM.METHODS: Patients completed the BOMET-QoL-10 questionnaire, the Visual Analogue Scale (VAS) for pain, and a self-perceived health status item at baseline and at follow-up visits. We performed psychometric tests and calculated the effect size of specific BM treatment on patients´ HRQoL.RESULTS: Almost 70% of the 172 patients reported symptoms, 23.3% experienced irruptive pain, and over half were receiving chemotherapy. BOMET-QoL-10 proved to be a quick assessment tool performing well in readability and completion time (about 10 min) with 0-1.2% of missing/invalid data. Although BOMET-QoL-10 scores remained fairly stable during study visits, differences were observed for patient subgroups (e.g., with or without skeletal-related events or adverse effects). Scores were significantly correlated with physician-reported patient status, patient-reported pain, symptoms, and perceived health status. BOMET-QoL-10 scores also varied prospectively according to changes in pain intensity.CONCLUSIONS: BOMET-QoL-10 performed well as a brief, easy-to-administer, useful, and sensitive HRQoL measure for potential use for clinical practice with MBC patients.TRIAL REGISTRATION: NCT03847220. Retrospectively registered on clinicaltrials.gov (February the 20th 2019).",

author = "A Barnadas and M Mu{\~n}oz and M Margel{\'i} and Chac{\'o}n, {J I} and J Cassinello and S Antolin and E Adrover and M Ramos and E Carrasco and Jimeno, {M A} and B Ojeda and X Gonz{\'a}lez and S Gonz{\'a}lez and M Constenla and J Flori{\'a}n and A Miguel and A Llombart and A Lluch and M Ruiz-Borrego and R Colomer and {Del Barco}, S",

year = "2019",

month = dec,

day = "21",

doi = "10.1186/s41687-019-0161-y",

language = "English",

volume = "3",

pages = "72",

journal = "Journal of Patient-Reported Outcomes",

issn = "2509-8020",

publisher = "Springer International Publishing AG",

number = "1",

}

Barnadas, A, Muñoz, M, Margelí, M, Chacón, JI, Cassinello, J, Antolin, S, Adrover, E, Ramos, M, Carrasco, E, Jimeno, MA, Ojeda, B, González, X, González, S, Constenla, M, Florián, J, Miguel, A, Llombart, A, Lluch, A, Ruiz-Borrego, M, Colomer, R & Del Barco, S 2019, 'BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study', Journal of Patient-Reported Outcomes, vol. 3, no. 1, pp. 72. https://doi.org/10.1186/s41687-019-0161-y

TY - JOUR

T1 - BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis

T2 - the prospective MABOMET GEICAM study

AU - Barnadas, A

AU - Muñoz, M

AU - Margelí, M

AU - Chacón, J I

AU - Cassinello, J

AU - Antolin, S

AU - Adrover, E

AU - Ramos, M

AU - Carrasco, E

AU - Jimeno, M A

AU - Ojeda, B

AU - González, X

AU - González, S

AU - Constenla, M

AU - Florián, J

AU - Miguel, A

AU - Llombart, A

AU - Lluch, A

AU - Ruiz-Borrego, M

AU - Colomer, R

AU - Del Barco, S

PY - 2019/12/21

Y1 - 2019/12/21

N2 - BACKGROUND: Bone metastasis (BM) is the most common site of disease in metastatic breast cancer (MBC) patients. BM impacts health-related quality of life (HRQoL). We tested prospectively the psychometric properties of the Bone Metastasis Quality of Life (BOMET-QoL-10) measure on MBC patients with BM.METHODS: Patients completed the BOMET-QoL-10 questionnaire, the Visual Analogue Scale (VAS) for pain, and a self-perceived health status item at baseline and at follow-up visits. We performed psychometric tests and calculated the effect size of specific BM treatment on patients´ HRQoL.RESULTS: Almost 70% of the 172 patients reported symptoms, 23.3% experienced irruptive pain, and over half were receiving chemotherapy. BOMET-QoL-10 proved to be a quick assessment tool performing well in readability and completion time (about 10 min) with 0-1.2% of missing/invalid data. Although BOMET-QoL-10 scores remained fairly stable during study visits, differences were observed for patient subgroups (e.g., with or without skeletal-related events or adverse effects). Scores were significantly correlated with physician-reported patient status, patient-reported pain, symptoms, and perceived health status. BOMET-QoL-10 scores also varied prospectively according to changes in pain intensity.CONCLUSIONS: BOMET-QoL-10 performed well as a brief, easy-to-administer, useful, and sensitive HRQoL measure for potential use for clinical practice with MBC patients.TRIAL REGISTRATION: NCT03847220. Retrospectively registered on clinicaltrials.gov (February the 20th 2019).

AB - BACKGROUND: Bone metastasis (BM) is the most common site of disease in metastatic breast cancer (MBC) patients. BM impacts health-related quality of life (HRQoL). We tested prospectively the psychometric properties of the Bone Metastasis Quality of Life (BOMET-QoL-10) measure on MBC patients with BM.METHODS: Patients completed the BOMET-QoL-10 questionnaire, the Visual Analogue Scale (VAS) for pain, and a self-perceived health status item at baseline and at follow-up visits. We performed psychometric tests and calculated the effect size of specific BM treatment on patients´ HRQoL.RESULTS: Almost 70% of the 172 patients reported symptoms, 23.3% experienced irruptive pain, and over half were receiving chemotherapy. BOMET-QoL-10 proved to be a quick assessment tool performing well in readability and completion time (about 10 min) with 0-1.2% of missing/invalid data. Although BOMET-QoL-10 scores remained fairly stable during study visits, differences were observed for patient subgroups (e.g., with or without skeletal-related events or adverse effects). Scores were significantly correlated with physician-reported patient status, patient-reported pain, symptoms, and perceived health status. BOMET-QoL-10 scores also varied prospectively according to changes in pain intensity.CONCLUSIONS: BOMET-QoL-10 performed well as a brief, easy-to-administer, useful, and sensitive HRQoL measure for potential use for clinical practice with MBC patients.TRIAL REGISTRATION: NCT03847220. Retrospectively registered on clinicaltrials.gov (February the 20th 2019).

U2 - 10.1186/s41687-019-0161-y

DO - 10.1186/s41687-019-0161-y

M3 - Article

C2 - 31865481

SN - 2509-8020

VL - 3

SP - 72

JO - Journal of Patient-Reported Outcomes

JF - Journal of Patient-Reported Outcomes

IS - 1

ER -

BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this